Latest News: Technology |  Celebrity |  Movies |  Apple |  Cars |  Business |  Sports |  TV Shows |  Geek

Trending

Filed under: News

 

Johnson & Johnson Faces Uphill Battle At FDA Advisory Panel

Jan 14 2014, 2:16pm CST | by

Johnson & Johnson Faces Uphill Battle At FDA Advisory Panel

Photo Credit: Forbes
 
 

The third time may not be the charm. Twice before the FDA has turned down the supplemental new drug application for an acute coronary syndrome indication for Johnson & Johnson’s Xarelto (rivaroxaban). On Thursday the Cardiovascular and Renal Drugs Advisory Committee will take up the sNDA yet again, but FDA review documents posted today suggest that the company will again face an uphill battle.

Originally, back in 2011, most observers thought the ACS indication would be a snap. The pivotal title="ATLAS ACS 2-TIMI 51: Rivaroxaban Beneficial in Low-Risk ACS Population">ATLAS ACS 2-TIMI 51 trial was widely praised when it came out and the FDA promptly granted priority review for the indication. But  momentum, as I’ve reported before, ground to a halt when FDA reviewers raised questions about the ATLAS trial. The FDA advisory panel, highlighted by vocal criticisms from Steve Nissen and Sanjay Kaul, resulted in a vote against the ACS indication, leading to the first complete response letter. The FDA issued a second complete response letter last March but J&J restated its confidence in the trial and its commitment to pursue the indication.

The earlier rejections were based largely on the significant amounts of missing followup data from the trial. The FDA and J&J thought that this problem might be circumvented by pursuing an indication for a shorter 90-day treatment duration, since much of the missing data was for longer followup. But the short term data do not appear very convincing and the FDA reviewers make clear in the new review documents that they now have grave concerns about this approach. (For readers interested in the details and minutiae of FDA-sponsor interactions and negotiations, the briefing documents contain a series of letters from the FDA that provide a fascinating retrospective view of this complex process.)

There was more bad news for J&J in the announcement of the panel participants. Former critics Steve Nissen and Sanjay Kaul are on the roster again and will be joined by noted pharma critic Sidney Wolfe. In addition, and perhaps even more dangerous for J&J, is one of the scheduled FDA presenters, clinical reviewer Thomas Marciniak. He has become well known for his scathing reviews of rosiglitazone and the angiotensin receptor blockers in addition to rivaroxaban.

Source: Forbes

iPad Air Giveaway. Win a free iPad Air.

You Might Also Like

Updates

Shopping Deals

 
 
 

<a href="/latest_stories/all/all/31" rel="author">Forbes</a>
Forbes is among the most trusted resources for the world's business and investment leaders, providing them the uncompromising commentary, concise analysis, relevant tools and real-time reporting they need to succeed at work, profit from investing and have fun with the rewards of winning.

 

 

Comments

blog comments powered by Disqus

Latest stories

Leaked iPhone 6 manual shows brand new design
Leaked iPhone 6 manual shows brand new design
The card shows a diagram of all buttons on the Apple iPhone 6
 
 
iPhone 6 &#039;Phosphorus&#039; Component Likely a Barometric Pressure Sensor
iPhone 6 'Phosphorus' Component Likely a Barometric Pressure Sensor
The iPhone 6 has been rumored to include a number of new environmental sensors such as an atmospheric pressure sensor.
 
 
Deion Sanders' School Opens Despite Losing Charter
Deion Sanders' School Opens Despite Losing Charter
Pro Football Hall of Famer Deion Sanders' Prime Prep Academy in Fort Worth, Tex. opened this week despite its location -- in a shopping center across an adult shop -- being disapproved and losing its charter.
 
 
Google sets up a giant Google Maps search terminal in Shibuya
Google sets up a giant Google Maps search terminal in Shibuya
The main goal here is obviously to promote tourism. It also gives the tech giant an opportunity to promote its products, particularly Google Maps.
 
 
 

About the Geek Mind

The “geek mind” is concerned with more than just the latest iPhone rumors, or which company will win the gaming console wars. I4U is concerned with more than just the latest photo shoot or other celebrity gossip.

The “geek mind” is concerned with life, in all its different forms and facets. The geek mind wants to know about societal and financial issues, both abroad and at home. If a Fortune 500 decides to raise their minimum wage, or any high priority news, the geek mind wants to know. The geek mind wants to know the top teams in the National Football League, or who’s likely to win the NBA Finals this coming year. The geek mind wants to know who the hottest new models are, or whether the newest blockbuster movie is worth seeing. The geek mind wants to know. The geek mind wants—needs—knowledge.

Read more about The Geek Mind.